米罗巴林用于全髋关节置换术后疼痛管理的随机对照试验
结果显示米罗巴林未显著减少24小时阿片类药物消耗量或疼痛评分,但困倦/镇静和头痛等中枢神经系统不良事件发生率显著升高。结论不支持常规使用米罗巴林作为全髋关节置换术多模式镇痛的一部分。
要点
- 米罗巴林组24小时吗啡当量消耗量数值上低于对照组,但差异无统计学意义。
- 米罗巴林组困倦/镇静发生率56.8%显著高于对照组28.3%(P=0.01)。
- 米罗巴林组头痛发生率13.6%显著高于对照组0%(P=0.011)。
核心结论
- 围手术期米罗巴林未减少全髋关节置换术后阿片类药物消耗量或术后疼痛。
- 米罗巴林与中枢神经系统相关不良事件发生率增加相关。
- 研究结果不支持将米罗巴林常规用于初次全髋关节置换术的多模式镇痛。
研究设计与样本
- 前瞻性、单中心、开放标签、评估者盲法随机对照试验。
- 纳入成人初次全髋关节置换术患者,按1:1随机分为米罗巴林组(n=44)和对照组(n=46)。
- 米罗巴林组术前口服,术后15 mg每日两次,连续两天;对照组不加用额外药物。
- 所有患者均接受标准化麻醉和多模式镇痛,包括对乙酰氨基酚、非甾体抗炎药和芬太尼患者自控镇痛。
- 主要结局为累积24小时吗啡当量消耗量。
主要发现
- 24小时吗啡当量消耗量米罗巴林组为14.6 ± 20.1 mg,对照组为22.0 ± 35.0 mg,组间平均差异-7.42 mg(95%CI -19.44至4.60;Welch P=0.223),无统计学意义。
- 体重标准化阿片类药物使用量两组无差异。
- 重复测量分析显示各时间点数字评定量表评分组间无显著差异。
- 中枢神经系统相关不良事件米罗巴林组更常见,困倦/镇静发生率56.8% vs 28.3%(P=0.01),头痛13.6% vs 0%(P=0.011)。
- 恶心和呕吐发生率两组无差异,早期功能恢复两组相似。
关键数值与推荐
- 主要结局指标为累积24小时吗啡当量消耗量。
- 次要结局包括术后2、4、24、48小时静息及被动或主动运动时数字评定量表疼痛评分和不良事件(困倦/镇静、头痛、恶心、呕吐)。
临床怎么用
- 在全髋关节置换术多模式镇痛中,不应常规加用米罗巴林。
- 若考虑使用米罗巴林,需警惕困倦/镇静和头痛等中枢神经系统不良事件。
局限性
- 单中心、开放标签设计可能引入偏倚。
- 样本量较小(米罗巴林组44例,对照组46例)。
- 仅评估术后48小时内结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mirogabalin, a selective α2δ-1 ligand, has been proposed to exhibit potent analgesic effects with fewer central nervous system (CNS) side effects than prior gabapentinoids. Its effectiveness for acute postoperative pain after total hip arthroplasty (THA) remains uncertain. METHODS: This study was conducted as a prospective, single-center, open-label, assessor-blinded randomized trial. Adult patients undergoing primary THA were randomized in a 1:1 ratio to receive either oral mirogabalin (administered preoperatively, followed by 15 mg twice daily for two postoperative days; n = 44) or no additional drug (control group; n = 46). All patients also received standardized anesthesia and multimodal analgesia, including acetaminophen, nonsteroidal anti-inflammatory drugs, and fentanyl-based patient-controlled analgesia. The primary outcome was a cumulative 24-hour morphine equivalent consumption. The secondary outcomes included numeric rating scale pain scores at rest and during passive or active motion at two, four, 24, and 48 hours, as well as adverse events (drowsiness/sedation, headache, nausea, and vomiting). RESULTS: At 24 hours, morphine equivalent consumption was numerically lower in the mirogabalin group compared with the control group (14.6 ± 20.1 versus 22.0 ± 35.0 mg), but the between-group mean difference was not statistically significant (-7.42 mg; 95% confidence interval -19.44 to 4.60; Welch P = 0.223). Similarly, weight-normalized opioid use showed no difference. Repeated-measures analyses showed no significant between-group differences in numeric rating scale at any time point. The CNS-related adverse events were more frequent in the mirogabalin group, notably drowsiness/sedation (56.8 versus 28.3%; P = 0.01) and headache (13.6 versus 0%; P = 0.011), whereas nausea and vomiting did not differ. Early functional recovery was similar between groups. CONCLUSIONS: Perioperative mirogabalin did not reduce opioid consumption or postoperative pain after THA and was associated with an increased incidence of CNS-related adverse events. These findings do not support the routine use of mirogabalin as part of multimodal analgesia for primary THA. LEVEL OF EVIDENCE: Level 2.
引用
- Takeda Y, Nakai T, Okamoto T, et al. Perioperative Administration of Mirogabalin for Postoperative Pain Management Following Total Hip Arthroplasty: A Randomized Controlled Trial. J Arthroplasty. 2026. PMID: 41951064. doi:10.1016/j.arth.2026.03.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。